Clearside Biomedical, Inc. (CLSD): Price and Financial Metrics
CLSD Price/Volume Stats
| Current price | $1.34 | 52-week high | $2.12 |
| Prev. close | $1.26 | 52-week low | $0.65 |
| Day low | $1.27 | Volume | 154,200 |
| Day high | $1.38 | Avg. volume | 335,169 |
| 50-day MA | $1.45 | Dividend yield | N/A |
| 200-day MA | $1.15 | Market Cap | 100.13M |
CLSD Stock Price Chart Interactive Chart >
Clearside Biomedical, Inc. (CLSD) Company Bio
Clearside Biomedical, a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. The company was founded in 2011 and is based in Alpharetta, Georgia
Latest CLSD News From Around the Web
Below are the latest news stories about CLEARSIDE BIOMEDICAL INC that investors may wish to consider to help them evaluate CLSD as an investment opportunity.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS Microinjector® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has completed randomization |
Can Clearside Biomedical (NASDAQ:CLSD) Afford To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although... |
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call TranscriptClearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript November 13, 2023 Clearside Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.16. Operator: Greetings, and welcome to the Clearside Biomedical Third Quarter 2023 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode and a question-and-answer […] |
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, and Sales Based Milestone Payments, Plus Royalties - - Recruitment Completed in CLS-AX Phase 2b ODYSSEY Wet AMD Trial with Topline Data Expected in Q3 2024 - - Management to Host Webcast and Conference Call Today at 4:30 |
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare ConferenceALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m. ET in New York, NY. A link to the live and archived webca |
CLSD Price Returns
| 1-mo | -12.42% |
| 3-mo | 8.94% |
| 6-mo | 94.48% |
| 1-year | 32.67% |
| 3-year | -57.99% |
| 5-year | 7.20% |
| YTD | 14.53% |
| 2023 | 4.46% |
| 2022 | -59.27% |
| 2021 | 0.36% |
| 2020 | -5.52% |
| 2019 | 171.03% |
Continue Researching CLSD
Want to do more research on Clearside Biomedical Inc's stock and its price? Try the links below:Clearside Biomedical Inc (CLSD) Stock Price | Nasdaq
Clearside Biomedical Inc (CLSD) Stock Quote, History and News - Yahoo Finance
Clearside Biomedical Inc (CLSD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...